NASDAQ:BTAI BioXcel Therapeutics Q1 2026 Earnings Results & Report BioXcel Therapeutics missed analyst expectations on both earnings and revenue in its Q1 2026 results, released May 15, 2026. The company reported EPS of -$0.54 versus the -$0.5325 consensus estimate, while revenue of $206 thousand fell short of the $381 thousand estimate by $175.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 15, 2026TimeBefore Market OpensConference Call7:00 AM ET BioXcel Therapeutics EPS ResultsActual EPS-$0.54Consensus EPS -$0.5325Beat/MissMissed by -$0.0075One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersBioXcel Therapeutics Revenue ResultsActual Revenue$206 thousandExpected Revenue$381 thousandBeat/MissMissed by -$175.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) BioXcel Therapeutics Q1 2026 Earnings FAQ Did BioXcel Therapeutics beat earnings estimates for Q1 2026? BioXcel Therapeutics (NASDAQ:BTAI) reported earnings of -$0.54 per share for Q1 2026, missing the consensus estimate of -$0.5325. The report was announced on Friday, May 15, 2026. What was BioXcel Therapeutics' revenue for Q1 2026? BioXcel Therapeutics reported revenue of $206 thousand for Q1 2026, against a consensus estimate of $381 thousand. BioXcel Therapeutics Earnings HeadlinesBioXcel Therapeutics Transitions to BX Liquidation VehicleOctober 30, 2026 | tipranks.comBiotech Gainers: BTAI Asset Deal, BIAF CyPath Growth, CYPH Zcash, GRI Pipeline Drive GainsSeptember 3, 2026 | rttnews.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 12 at 1:00 AM | Profits Run (Ad)BioXcel Therapeutics, Inc.(NasdaqCM:BTAI) dropped from S&P TMI IndexSeptember 2, 2026 | marketscreener.comMBioXcel Therapeutics Enters Asset Sale Agreement With Teva Pharmaceuticals; Stock DownAugust 31, 2026 | rttnews.comBioXcel Therapeutics Initiates Chapter 11 and Sale ProcessAugust 30, 2026 | theglobeandmail.comSee More BioXcel Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioXcel Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioXcel Therapeutics and other key companies, straight to your email. Email Address About BioXcel TherapeuticsBioXcel Therapeutics (NASDAQ:BTAI) is a biopharmaceutical company focused on developing medicines for neuroscience and immuno-oncology indications. The company uses an artificial intelligence-driven drug development platform to identify and advance therapies by analyzing existing clinical and biomedical data, with the goal of improving the efficiency of drug discovery and development. BioXcel’s primary commercial product is IGALMI (dexmedetomidine) sublingual film, which the U.S. Food and Drug Administration approved in 2022 for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults. The product is designed for administration under the tongue and is intended for use in a monitored healthcare setting. BioXcel Therapeutics is headquartered in New Haven, Connecticut, and has focused its clinical and commercial activities primarily on the U.S. market. The company was led by co-founder and Chief Executive Officer Vimal Mehta, who has overseen its efforts to develop AI-enabled therapies and expand the use of its neuroscience-focused product portfolio.View BioXcel Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
